Drug Trial Radar · NCT02677922
A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy
Last checked: Nov 19, 2026Latest source record: Feb 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
130
Actual
Start
Jun 3, 2016
Primary completion
Aug 2, 2018
Study completion Sep 30, 2026
Sponsor
- Lead sponsor
- CelgeneBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Feb 9, 2016
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study are 1. to determine the recommended combination dose of AG-120 and AG-221 separately when administered with azacitidine and, 2. to investigate the safety, tolerability, and efficacy of the combinations of AG-120 with azacitidine and AG-221 with azacitidine versus with azacitidine alone in participants with acute myeloid leukemia (AML) with the isocitrate dehydrogenase (IDH) enzyme isoforms 1 or 2 mutations, respectively.
Conditions
- Leukemia, Myeloid, Acute
Interventions
AG-120Drug
Specified dose on specified days
AzacitidineDrug
Specified dose on specified days
AG-221Drug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- The Number of Participants Experiencing Dose-limiting Toxicities (DLTs): Phase 1B (Dose Finding Stage)Time frame: From first dose to 28 days after first dose
- The Number of Participants Experiencing Adverse Events: Phase 1B (Dose Finding and Expansion Stage)Time frame: From first dose to 28 days after last dose (up to approximately 13 months)
- Overall Response Rate: Phase 2 (Randomized Stage)Time frame: From first dose up to approximately 26 months
Locations
49 sites in 14 countries. Site status is shown where the registry gives one.
Local Institution - 105
Duarte, California
Local Institution - 107
New Haven, Connecticut
Local Institution - 108
Chicago, Illinois
Local Institution - 103
Chicago, Illinois
Local Institution - 102
Boston, Massachusetts
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Local Institution - 902
Boston, Massachusetts
Local Institution - 106
New York, New York
Local Institution - 110
Dallas, Texas
Local Institution - 175
Melbourne, Australia
Local Institution - 177
Perth, Australia
Local Institution - 178
Adelaide, South Australia, Australia
Local Institution - UNK-121
Yvoir, Belgium
Local Institution - 125
Toronto, Ontario, Canada
Local Institution - 205
Lille, France
Local Institution - 206
Marseille, France
Local Institution - 200
Paris, France
Local Institution - 204
Pessac, France
Local Institution - 202
Pierre-Bénite, France
Local Institution - 203
Toulouse, France
Local Institution - 201
Villejuif, France
Local Institution - 227
Berlin, Germany
Local Institution - 230
Dresden, Germany
Local Institution - 225
Ulm, Germany
Local Institution - 253
Bologna, Emilia-Romagna, Italy
Local Institution - 252
Florence, Italy
Local Institution - 256
Genova, Italy
Local Institution - 251
Orbassano, Italy
Local Institution - 254
Padova, Italy
Local Institution - 250
Pesaro, Italy
Local Institution - 255
Roma, Italy
Local Institution - 277
Utrecht, Netherlands
Local Institution - 327
Lisbon, Portugal
Local Institution - 351
Seoul, South Korea
Local Institution - 350
Seoul, South Korea
Local Institution - 379
Barcelona, Spain
Local Institution - 375
Barcelona, Spain
Local Institution - 376
Cáceres, Spain
Local Institution - 378
Madrid, Spain
Local Institution - 381
Madrid, Spain
Showing 40 of 49 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.